DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) — GH Analysis PLC GHRS, a clinical-stage biopharmaceutical firm devoted to remodeling the therapy of psychiatric and neurological issues, at this time introduced that it’ll host a convention name and stay webcast on Monday, February 3, 2025, at 8.00 a.m. EST to supply an replace on knowledge from the randomized, double-blind, placebo-controlled Section 2b trial of GH001 in treatment-resistant melancholy (TRD).
To entry the convention name, please register prematurely here. A stay webcast of the decision will probably be obtainable underneath “Occasions & Shows” within the Buyers part of GH Analysis PLC’s web site at ghres.com.
About GH Analysis PLC
GH Analysis PLC is a clinical-stage biopharmaceutical firm devoted to remodeling the therapy of psychiatric and neurological issues. GH Analysis PLC’s preliminary focus is on creating its novel and proprietary mebufotenin therapies for the therapy of sufferers with treatment-resistant melancholy (TRD).
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin administration through a proprietary inhalation method. Primarily based on the noticed medical exercise in our accomplished section 1/2 GH001-TRD-102 trial, the place 87.5% of sufferers with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing routine within the Section 2 a part of the trial, we imagine that GH001 has the potential to vary the best way TRD is handled at this time.
Investor Relations
Julie Ryan
GH Analysis PLC
[email protected]
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
